Additionally, ectopic expression of GAS5 reduced the viability of HCT116R cells after treatment with various anti-cancer reagents such as doxorubicin (DOX), oxaliplatin (OXP), cisplatin (CDDP), and tamoxifen (TAM) (Figure 6C), which implies that GAS5 helps to improve drug response in resistant cells. The gene discussed is GAS5; the disease is cancer.